Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNOC022 targeted drug combinations for malignant midline glioma in children and young adults
MOH_2022-09-05_012027Phase 2Not yet recruiting
- Sponsor
- דר מיכל ילון
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dordaviprone, panobinostat and paxalisib in diffuse midline glioma (DMG), sponsored by דר מיכל ילון. Primary endpoint: Time to recurrence. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
dordavipronepanobinostatpaxalisib
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on MOH_2022-09-05_012027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-05_012027.